Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Anlotinib in Acral Malignant Melanoma
NCT05087602Phase 2Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, anlotinib in acral lentiginous melanoma (ALM), sponsored by Qilu Hospital of Shandong University. Status: unknown.
02
Drugs
toripalimabanlotinib
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT05087602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087602.